Date: Sunday, May 14-1-4pm PDT160 E Tasman Dr Address: 160 East Tasman Drive San Jose, CA 95134 United States Organizer: CBA (Chinese Bioscience Association) Co-organizers: Medicilon, Q BAY center Media partner: CABS (Chinese-American Bio/Pharmaceutical Society) Gene- and RNA-based therapies show significant promise. Gene editing aims to treat genetic disease through altering gene expression. Programmable editing of nucleic acids offers significant therapeutic potential for a wide range of genetic diseases. Gene- and RNA-based therapies need substantial innovation to unlock full potential for patients. Scaling digital and analytics in discovery and R&D is part of the solution. Applying artificial intelligence (Al) to R&D for novel therapeutic modalities brings new opportunity. Let's explore the intersection of Al, gene editing, and RNA therapeutics! Dr. Ho Leung Ng the founder of Rise Bio Dr. Ng is the founder of Rise Bio, a startu...
Integrated Drug Discovery Services- Chemistry, Biology & Preclinical Services